Butterfly Medical's EU MDR certification: what device marketing learns from a two-market launch
Butterfly Medical's prostatic retraction device has been certified under EU MDR 2017/745 while its US review continues. For medtech marketing, the easy part is the announcement, and the craft is in what the copy claims next.
What Butterfly Medical's EU MDR certification actually says#
Butterfly Medical announced on 13 October 2026 that its Butterfly Prostatic Retraction Device has been certified under the European Union Medical Device Regulation, EU MDR 2017/745. The company develops a minimally invasive treatment for benign prostatic hyperplasia, BPH, and the announcement was made from Boston and Yokneam in Israel (the PR Newswire release).
The device's job is mechanical rather than surgical: it is designed to hold back prostatic tissue and improve urinary flow without cutting, burning or removing tissue, which is where it differs from many established BPH procedures (Third News coverage, Butterfly Medical). For device marketers, the interesting part is the paperwork trail. Third News reports the certification followed a pivotal clinical trial of 244 patients and the submission of a Premarket Approval application, a PMA, to the United States Food and Drug Administration (Third News coverage). For a device whose European milestone is an EU MDR certification, that transatlantic pairing is the story.
The wider MDR frame is worth stating precisely, because copy often blurs it. EU MDR 2017/745 replaced the old Medical Devices Directive and tightened clinical evidence and post-market obligations across the bloc. The regulation itself is published in the Official Journal of the European Union, and it is the text that CE marking claims actually rest on (Regulation (EU) 2017/745 on EUR-Lex). Manufacturers in this category typically work with notified bodies for years before a first certificate, which is why the announcement's brevity is normal: the paperwork story is long, and the press release is only its cover.
| Item | Value |
|---|---|
| 2017-05-05 | EU MDR published in the Official Journal |
| 2026-10-13 | Certification announced |
| 2026-10-20 | AdvaMed MedTech update due in Boston |
Two markets, two evidentiary bars#
The same device now sits at two different points in two regulatory systems, and the difference shapes every line of copy. In Europe, the EU MDR certification supports CE marking for the device within its certified scope. In the United States, Third News reports the device has yet to be approved by the FDA for commercial use, with the PMA application submitted and awaiting review (Third News, BPH device status). In short: CE marking in Europe under EU MDR, and a review file in America.
That split is the normal rhythm of device launches, and the FDA's own Premarket Approval process explains why the American bar is so high: PMA is the most stringent device pathway, reserved for high-risk devices and requiring valid scientific evidence of safety and effectiveness (the FDA's Premarket Approval page), the highest evidentiary bar in medical device regulation. A marketing team that treats a submitted PMA as a marketing milestone is borrowing trouble, because a submission is not a clearance and a clearance is not an approval.
| Market | Status | What copy can say |
|---|---|---|
| European Union | Certified under EU MDR, CE marking | Describe the certified intended purpose and the evidence behind it |
| United States | PMA submitted, not approved | Describe the trial programme and submission status only |
| Both | Pivotal study of 244 patients | Cite the study honestly, with limits and no outcome guarantees |
- European UnionCertified under EU MDR, CE markingDescribe the certified intended purpose and the evidence behind it
- United StatesPMA submitted, not approvedDescribe the trial programme and submission status only
- BothPivotal study of 244 patientsCite the study honestly, with limits and no outcome guarantees
One more pair of words to keep straight: cleared against approved. In the United States, cleared describes 510(k) authorisation for moderate-risk devices, while approved describes a granted PMA for high-risk devices. The phrases are not interchangeable in copy, and in device markets a swapped word can read as a claim about evidence the product does not have.
The condition itself is common and long-running, which is why the category attracts advertising as well as engineering. The prostate sits below the bladder and surrounds the urethra, so an enlarged prostate narrows the channel and produces the familiar symptoms, and treatment options range from medication to surgery (the NIDDK's enlarged prostate explainer). A minimally invasive option between those poles is a genuine story, and the vendor's own chief medical officer frames it exactly that way (Third News). For teams comparing pathways, the FDA's device hub is the cleanest starting point (the FDA's medical devices hub).
Dr James C. Ulchaker, Butterfly Medical's chief medical officer and an emeritus urologist at the Cleveland Clinic, told the release's coverage that BPH affects men differently and that patients deserve options suited to their needs, especially around avoiding tissue ablation or long-term pharmaceutical treatment (Third News, Ulchaker quote).
What this means for medtech marketing and medical device advertising#
Certification press releases are where medical device advertising is most often born badly. The pattern is familiar: a certification lands, a launch deck appears, and somewhere between the engineering facts and the sales slide the claims stretch past the evidence. The Butterfly announcement is a clean case study in doing it the other way, because the facts carry the story without embellishment. The fox does not need to shout; the trail does the work.
Three details in particular are the ones a medtech marketing agency should copy. First, the evidence is stated with its size: a pivotal study of 244 patients, not a vague clinical programme. Second, the risks travel with the claims, including urinary discomfort, urgency, frequency, bleeding and, in rare cases, device removal (Third News, risks and study details). Third, the milestone language stays exact: certification under a named regulation, not approval or clearance.
The CE marking distinction deserves its own line, because it is one of the most common slips in device copy. A CE mark indicates a device meets the requirements of the applicable EU legislation for its scope; it is not an endorsement of comparative superiority, and it says nothing about other markets. Writing that treats it as a badge rather than a scope invites the kind of challenge that none of the parties want.
Clinician quotes deserve the same care as numbers. A chief medical officer describing patient needs is credible context, and a paraphrase that turns that context into a performance claim is a new claim with no owner. Get quotes approved for marketing use as written, name the speakers accurately, and treat every translation as new copy rather than decoration.
The regulatory climate is moving too. The MHRA has published its research into public views on AI in healthcare, a reminder that device communication sits inside a wider conversation about evidence and trust (the MHRA report announcement). Trust is earned in detail. For device marketers, the detail is the study number, the pathway and the disclaimer block.
Europe's device sector bodies are worth following for the same reason. MedTech Europe carries the industry's positions on MDR implementation and the practical pinch points manufacturers still face (MedTech Europe). If the next phase of this launch involves European market access work, those positions will frame the conversation.
A two-market claims checklist for an EU-first launch#
For the launch teams watching this space, the playbook that follows certification is short, and it travels well across device categories, from urology to diagnostics. An EU MDR milestone changes the paperwork, not the claims discipline.
Write down the certified intended purpose exactly, and make it the boundary every claim must stay inside.
One set for territories where the device is certified, another for markets where review is still in progress.
Name the study size and design. Avoid superlatives and outcome guarantees the data does not carry.
Risks and caveats belong in the core template, not in a footer that legal adds later.
Track conference dates and review outcomes, and refresh copy as each one lands.
The diary is a claims tool because each milestone changes what the copy may say. A certification opens European scope language; a conference invite changes the speaker notes; a review outcome changes the whole US track. Teams that map those dates in advance write once per milestone instead of rewriting after each one.
- 244
patients in the pivotal study
- 2
markets, EU certified and US in review
- 20 Oct
AdvaMed update date in Boston
- 2017/745
the regulation the CE mark rests on
The conference diary matters more than it looks. Butterfly Medical is due to share further updates at the AdvaMed MedTech Conference on 20 October in Boston (Third News, AdvaMed plans, AdvaMed), and conference moments are when claims get spoken loosely and quoted widely, and a scent like that carries. A claims pack prepared before the flight beats a scramble after the headline.
For teams that want the longer version of this playbook, the healthcare marketing brief at healthcare marketing collects our device and clinic work, and the regulatory thread runs through most of it. The editorial side sits with content marketing, and discovery work with SEO and GEO services. Keep the pack close, keep the trail clean, and the next milestone takes care of itself.
The honest read#
Solid facts: the certification was announced on 13 October 2026 under EU MDR 2017/745; the device is minimally invasive and avoids tissue removal by design; the pivotal study covered 244 patients; a PMA has been submitted to the FDA and approval has not been granted; an AdvaMed update is due on 20 October in Boston. Uncertain: the notified body and certificate details, which the announcement did not include, and anything beyond the trial size about the clinical results. We found no EUDAMED reference in the material and will not pretend otherwise.
Two sentences any device team can use this week. After an EU MDR certification, the claims boundary is the certified scope, and copy that stays inside it does not need rescuing later. Before FDA action, US-facing copy describes the review, not the benefits.
If your launch calendar has a certification date on it this quarter, the sensible next move is a claims rehearsal: run the deck and the press release past the checklist above before either goes out. talk to folkfox is where to start if the rehearsal needs a second pair of eyes, and our folkfox work shows how we handle regulated categories end to end. A final housekeeping note: keep a dated log of every milestone and the copy change it triggered, so when the next regulator, conference or review asks a question, the answer is already filed.
Frequently asked questions#
What is EU MDR certification for a medical device?
EU MDR certification means a notified body has assessed the device against Regulation (EU) 2017/745 and confirmed conformity for a defined scope, which supports CE marking in the European Union. It is a European market approval, not a quality ranking, and it says nothing about approval in other markets.
Has Butterfly Medical's device been approved in the United States?
No. Third News reports that a Premarket Approval application has been submitted to the FDA and the device has yet to be approved for commercial use in the United States. A submitted PMA is a review milestone, and US-facing copy should describe the submission rather than claim availability.
What can device marketing claim after CE marking?
Claims should describe the certified intended purpose and the evidence behind it, with limits stated. Comparatives, outcome guarantees and superiority language need their own substantiation. The certification supports existence and conformity within scope; it does not license broader benefit claims.
Why do medical device adverts carry risk statements?
Because the regulatory framework expects balance between benefit and risk, and because claims without caveats invite challenge from regulators and clinicians alike. The Butterfly material lists urinary discomfort, urgency, frequency, bleeding and rare device removal, which is the standard the whole category works to.
What is the difference between FDA cleared and FDA approved?
Cleared usually refers to the 510(k) pathway for moderate-risk devices, while approved refers to Premarket Approval for high-risk devices. The distinction matters in copy: the phrases are not interchangeable, and using the wrong one in medical device advertising is a basic accuracy failure.
How should a medtech marketing agency plan an EU-first device launch?
Lock the certified scope, split copy by market, state evidence with its limits, carry the risk block in every template, and diary each regulatory milestone. An EU-first sequence means European materials can describe the certified device while US materials track the review honestly.
Read more on this topic#
Launching a regulated device into two markets?
folkfox writes healthcare and medtech marketing with the evidence, the limits and the disclaimers in place, so certification milestones become launch momentum rather than compliance clean-up.
Want folkfox in your Google results and AI answers? Set folkfox as a preferred source.